Alloy Therapeutics
Founded 2020 · CIK 0001851943 · Biotech · Private
ATX-Gx mouse model and antibody discovery platform
alloytx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $147M
- 3 Form D · Apr 2026
- 6 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 19
- 0 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $74,999,875 | |
| Private capital raised | Form D · SEC | $41,744,503 | |
| Private capital raised | Form D · SEC | $30,020,259 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2220 | Immuneering Corp | — | $77M |
| 2221 | Pheast Therapeutics | — | $50M |
| 2222 | Tmunity Therapeutics | — | $140M |
| 2223 | Alloy Therapeutics | — | $147M |
| 2224 | ArriVent Biopharma | — | $191M |
| 2225 | MOBIUS SCIENTIFIC INC. | — | — |
| 2226 | PMV Pharmaceuticals | — | $74M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Errik AndersonDirector · Executive Officer
- Piotr BobrowiczDirector · Executive Officer
- Jason CammDirector
- Jason ColomaDirector
- Alaa HalawaDirector
- Fabian HansenDirector
- Christian KanadyDirector
- Alex KolicichDirector
- Ulrik NielsenDirector
- Jay RosanelliExecutive Officer
- Logan SnyderDirector · Executive Officer
- Anthony SunDirector
Patents
- Methods For Identifying Cognate Immunoglobulin Pairs From Individual B Cellsapplication
- ANTI-CD3 Antibodies And Uses Thereofapplication
- ANTI-WT1/HLA-A2 Antibody And Uses Thereofapplication
- ANTI-CD3 Antibodies And Uses Thereofapplication
- Methods For Identifying Cognate Immunoglobulin Pairs From Individual B Cellsapplication
- ANTI-CD3 Antibodies And Uses Thereofapplication
- ANTI-CD3 Antibodies And Uses Thereofapplication
- ANTI-WT1/HLA-A2 Antibody And Uses Thereofapplication
- ANTI-WT1/HLA-A2 Antibody And Uses Thereofapplication
- ANTI-WT1/HLA-A2 Antibody And Uses Thereofapplication
- ANTI-CD22 Antibodies And Uses Thereofapplication
- ANTI-CD22 Antibodies And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.